key: cord-0701776-ypqi8i77
authors: Yadav, Pragya D; Sahay, Rima R; Sapkal, Gajanan; Nyayanit, Dimpal; Shete, Anita M; Deshpande, Gururaj; Patil, Deepak Y; Gupta, Nivedita; Kumar, Sanjay; Abraham, Priya; Panda, Samiran; Bhargava, Balram
title: Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta with individuals sera vaccinated with BBV152
date: 2021-09-28
journal: J Travel Med
DOI: 10.1093/jtm/taab154
sha: de8776c73df0abb3e9c5a4ae8346752e06b05894
doc_id: 701776
cord_uid: ypqi8i77

Sera of COVID-19 naive vaccinees, COVID-19 recovered cases with vaccination and breakthrough cases demonstrated 1.3, 2.5 and 1.9-fold reduction in neutralization titers against Delta and 1.5, 3.5, 2.8-fold against Delta AY.1 compared to B.1 respectively. However, high neutralization titers would still effectively protect against Delta, Delta AY.1 and B.1.617.3 variants.

India. 1 It has spread across 112 countries and found to be more infectious than the Alpha, Beta and Gamma variants. Reduced neutralization has been reported with the sera of individuals vaccinated with BNT162b2, BBV152/Covaxin and chAdOx1-s against Delta variant in recent reports. 2, 3 Delta variant has also been identified as the leading cause of breakthrough infections globally among vaccinated individuals. 4 Delta variant with its characteristic spike protein mutations (L452R, T478K, D614G

and P681R) has mutated further into four sub-lineages with additional mutations which are associated with higher transmission and probable immune escape. 1 

, M (I82T), ORF7a (V82A, T120I), ORF7b (T40I), ORF8 (del119/120) and N (D63G, R203M, G215C, D377Y) which probably enhances the ability to escape immune response and becomes a major concern for the ongoing vaccination programs. 5 The second wave of the SARS-CoV-2 pandemic was devastating for public health system of India and breakthrough cases were reported during this period. Besides this, the association of Delta variant in the breakthrough cases created serious concerns among the public health experts regarding the effectiveness of the available COVID-19 vaccines.

Considering this, we conducted this study to determine the neutralization potential in sera of the BBV152 vaccinated individuals against Delta and Delta AY.1 variant.

Here, we present the data from a cross-sectional study, where the sera of the fully vaccinated study participants with two doses of BBV152 vaccine were evaluated for neutralizing antibodies. The participants were divided in three separate groups viz. COVID-19 naïve vaccinees (CNV), COVID-19 recovered cases (real time RT-PCR positive) and vaccinated (CRV) and breakthrough infections post vaccination (BTI). The data of the variants responsible for SARS-CoV-2 infection in CRV and BTI groups was not available.

However, the participants of CRV group were infected before the emergence of Delta (Figure 1a-d) .

The 

PDY contributed to study design, data analysis, interpretation and writing. RRS, GS, GRD, DAN, AMS, DYP and SK contributed to data collection, data analysis, interpretation and writing. PA, NG, SP, and BB contributed to the critical review and finalization of the paper.

Authors do not have a conflict of interest among themselves.

The The statistical significance was assessed using a two-tailed Kruskal Wallis test with Dunn's test of multiple comparisons was performed to analyze the statistical significance. NAb titer of individual sera vaccinated with two doses of BBV152 (e), recovered cases administered with two doses of BBV152 (f) and breakthrough cases (g). A matched pair two-tailed pairwise comparison was performed using the Wilcoxon signed-rank test to analyze the statistical significance. Anti-SARS-CoV-2 IgG titers of vaccinated individual's sera for inactivated SARS-CoV-2, dotted lines represents the cut-off value of the assay (100) (h), S1-RBD protein, dotted lines represents the cut-off value of the assay (50) (i) and N protein, dotted lines represents the cut-off value of the assay (50) (j). The statistical significance was assessed using a two-tailed Kruskal-Wallis test with Dunn's test of multiple comparisons. P-value less than 0.05 were considered to be statistically significant for the tests applied. The dotted line on the figures indicates the limit of detection of the assay.

Data are presented as mean values +/− standard deviation (SD).

PANGO lineages

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

PANGO lineages

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Predominance of delta variant among the COVID-19 vaccinated and unvaccinated individuals